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Abstract
A high proportion of diabetic subjects are referred with athero-
sclerotic disease and higher risk for cardiovascular events. Rapid 
expansion of the use of non-invasive coronary and peripheral 
arteries imaging, facilitated by technological advances, have 
found diagnostic and prognostic roles in this population. This 
review, which includes important and actual works, guidelines, 
and algorithms on cardiovascular disease in the diabetic popula-
tion, indicates mandatory screening for arterial disease in these 
patients in light of their appropriate management.
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Introduction
The prognosis of patients with diabetes mellitus depends on 
the presence of vascular disease. Coronary artery disease (CAD) 
is the leading cause of death in people with diabetes mellitus. It 
has been reported that the 7-year cardiovascular mortality rate 
among patients with type 2 diabetes without a prior history of 
myocardial infarction is as high as that in non-diabetic patients with 
previous infarction [1]. Since the risk for complications due to 
CAD can be modified by appropriate interventions, early detection 
is important [2]. Because of this high risk of CAD and the poor 
outcome among asymptomatic patients with type 2 diabetes, clini-
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cians should use aggressive strategies to diagnose CAD to reduce 
or prevent cardiovascular morbidity and mortality in these patients.
Several factors are known to differentiate CAD in patients with 
diabetes from CAD in non-diabetic patients. These factors may 
provide clues as to the differences in prognosis for patients with 
diabetes, as well as suggest the limitations of available testing 
methods. For example, although atherosclerotic plaque appears to 
be morphologically similar among patients with or without diabetes, 
pathologic studies have demonstrated that coronary arteries in 
patients with diabetes and CAD show diffuse disease, in contrast 
to the more localized involvement often seen in the absence of 
diabetes [4]. Symptoms of myocardial ischaemia are often absent 
or atypical in diabetic patients, and CAD is frequently detected at 
an advanced stage, characterized by extensive atherosclerotic ob-
structive coronary disease. Diabetes also is associated with gen-
eralized endothelial dysfunction and small-vessel abnormalities, 
in addition to the larger-vessel abnormalities seen in non-diabetic 
patients with CAD [4, 5].
There are two points of view for the interplay of peripheral 
arterial disease (PAD) and cerebrovascular disease (CVD) with 
diabetes: The higher prevalence of PAD and CVD presented in the 
diabetic population than in the general population, and secondly 
that peripheral atherosclerosis is a marker of general atheroscle-
rosis in these patients [6]. Peripheral arterial disease occurs in 
diabetics with a 3-fold higher risk than in the general population. 
Prognosis of patients with PAD and diabetes depends on future 
cardiovascular events, which are two to four times more frequent 
than in the general population [7–8].
Diabetes is also one of the most important risk factors for 
development of cerebrovascular disease, defined as ischaemic 
stroke or asymptomatic carotid stenosis [9, 10]. The relative risk for 
stroke in diabetic subjects is 2.1–5.8 [6]. Development of carotid 
atherosclerosis in diabetic subjects is related to glycaemia and 
plasma cholesterol LDL and non-HDL level [11–14].
The clinical role of imaging atherosclerosis
Technological advances have facilitated a rapid expansion 
in the use of non-invasive coronary and peripheral arteries ima-
ging. There are now numerous options offering enhanced image 
quality and better anatomic definition, which were previously 
unavailable without catheterization. These less invasive imaging 
procedures are becoming important gatekeepers, helping to 
select patients for catheterization in anticipation of treatment. 
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Various non-invasive tests are available to identify patients at high 
risk of atherosclerotic disease, including myocardial perfusion 
scintigraphy, stress echocardiography, calcium scanning, cardiac 
MRI, multi-sliced MSCT angiography, and vascular ultrasound. 
Stress myocardial perfusion imaging 
with gated SPECT
The use of standard exercise ECG testing in patients with 
diabetes continues to be an area of concern and controversy. In ad-
dition to having decreased exercise capacity, diabetic patients of-
ten experience no chest pain during exercise, and the standard 
exercise ECG may be less reliable for detecting significant CAD 
in diabetic patients [15, 16]. Painless ST-segment depression 
during treadmill exercise is common in diabetic persons, and the 
diagnostic specificity of ST depression is often reduced in these 
patients [17].
Given the prevalence of CAD in patients with type 2 diabetes, 
the American Diabetes Association (ADA) recommends performing 
a cardiovascular risk assessment at least yearly [18]. In addition, 
the ADA recommends exercise stress testing in all asymptomatic 
patients with diabetes. The optimal frequency of stress testing 
is unknown although it has been suggested that stress testing 
should be considered every 3 to 5 years for asymptomatic pa-
tients with no new risk factors [19]. For patients with multiple or 
new risk factors, testing should be increased to every 1 to 2 years. 
Exercise ECG testing has a relatively high specificity and sensitivity 
(68% and 77%, respectively) [3], but often diabetic patients can-
not perform an exercise test because of complications such 
as leg ischaemia or lower cardiorespiratory capacity. In general, 
exercise-ECG may not be ideal due to the lower accuracy for as-
sessment of ischaemia and the inability of a substantial amount 
of patients with diabetes to perform an exercise test. The lower 
accuracy of exercise-ECG may be, in part, related to the ischaemic 
cascade, in which ECG abnormalities occur late in the cascade. 
The combination of imaging and stress testing may thus be 
preferred for assessment of myocardial ischaemia. Imaging al-
lows visualization of induction of perfusion (using nuclear imaging) 
or systolic wall motion abnormalities (mainly echocardiography, 
but magnetic resonance imaging can also be used), both sensi-
tive markers of ischaemia. In addition, the imaging studies can 
be performed in combination with pharmacological stress, rather 
than physical exercise, when needed. A large body of evidence 
attests to the high diagnostic yield of stress myocardial perfusion 
imaging and its important incremental prognostic value over both 
clinical and angiographic variables for the prediction of major acute 
coronary events [19, 20]. The degree and extent of myocardial 
perfusion abnormalities observed in stress myocardial perfusion 
abnormalities are related directly to outcome. The greater the 
myocardial perfusion abnormality, the greater the likelihood of 
future cardiac events. On the other hand, unequivocally normal 
stress myocardial perfusion imaging is associated with an excel-
lent outcome and a cardiac event rate of < 1% per year [17, 21]. 
Several investigators have reported that single-photon emission 
computed tomography (SPECT) myocardial perfusion imaging 
had similar prognostic value in patients with diabetes mellitus.
Giri et al. [13] evaluated stress SPECT myocardial perfusion 
imaging for risk stratification of patients with diabetes mellitus. In 
this multicentre, database analysis involving a large number of 
subjects, patients with diabetes mellitus had a significantly higher 
cardiac event rate (death and myocardial infarction) than that of 
the non-diabetic patient cohort. When adjustment was made for 
clinical variables and SPECT myocardial perfusion imaging results, 
however, cardiac survival was comparable, indicating that myocar-
dial perfusion imaging prognostic categorization supersedes the 
adverse predictive value of diabetes mellitus as a univariable 
parameter. Interestingly, women had a worse outcome for any 
given extent of myocardial perfusion abnormality than men did. Of 
substantial clinical interest was the observation that after the index 
study, patients with diabetes mellitus and normal stress SPECT 
images had a significantly higher two-year cardiac event rate 
than that of patients without diabetes. This prognostic finding is in 
marked contrast to the experience in the non-diabetic population, 
in which the association of normal myocardial perfusion imaging 
and excellent outcome has been demonstrated repeatedly [19, 23]. 
Defining the factors responsible for this altered prognostic value 
of normal myocardial perfusion imaging in diabetic patients will 
require further study. However, patients with diabetes mellitus and 
normal stress images may require more frequent follow-up testing. 
Current radionuclide imaging guidelines have reported the average 
sensitivities and specificities of exercise and vasodilator stress per-
fusion single-photon emission computed tomography (SPECT) for 
detecting angiographically significant CAD (Table 1). Generally un-
corrected for referral bias, the sensitivities average 87% for exercise 
and 89% for vasodilator stress, and the specificities average 73% 
for exercise and 75% for vasodilator stress [22, 24].
When to do cardiac screening with myocardial 
perfusion imaging in patients with diabetes
The ADA recommends annual evaluation of patients with 
diabetes. Exercise electrocardiography (ECG) is recommended 
as the initial screening tool to help identify patients who would be 
considered at higher-than-average risk of cardiac events [35]. 
Candidates for myocardial perfusion imaging include patients with:
— typical or atypical signs or symptoms of CAD;
— an abnormal resting ECG;
— peripheral or carotid arterial disease;
— age over 35, a sedentary lifestyle, and plans to initiate an 
exercise program;
— two or more of the following, in addition to diabetes: 
a) elevated total and low-density cholesterol or low high-den-
sity cholesterol; elevated blood pressure; smoking; family 
history of premature CAD or 
b) positive microalbuminuria or macroalbuminuria;
— inadequate exercise electrocardiographic results;
— no symptoms but mildly or moderately positive exercise elec-
trocardiograms (ECGs);
— clear or suggestive evidence of ischaemia or infarction on 
baseline ECG;
— mild angina and normal or near-normal ECGs. 
For patients at low risk of cardiovascular events, a standard 
treadmill exercise test is often chosen. However, if a diabetic pa-
tient has typical angina or Q waves on a resting ECG, myocardial 
perfusion imaging should be performed to assess ventricular 
function and obtain quantitative information on the extent of the 
perfusion abnormality [2]. 
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In non-diabetic patients, the low event rate in the presence of 
a normal study is maintained for years, but in diabetic patients, 
the so-called warranty period of a normal study is limited to 2–3 
years, indicating the rapid progression of coronary artery disease 
in these patients. For example, Elhendy et al. [5] demonstrated 
that the event rate in diabetic patients with a normal exercise 
echocardiogram increased from 0% in the first year to 1.8% at 
3-year follow-up and 7.6% at 5-year follow-up. 
Still, the available data reveal a high incidence of patients with 
silent ischaemia among asymptomatic patients with type 2 diabe-
tes. For example, in the Detection of Silent Myocardial Ischaemia 
in Asymptomatic Diabetics (DIAD) study, 22% of patients exhibited 
evidence of silent myocardial ischaemia on nuclear myocardial 
perfusion imaging [26]. Of interest, 41% of all abnormal SPECT stu-
dies occurred in patients with less than two risk factors. Moreover, 
multivariate analysis demonstrated that only autonomic dysfunc-
tion was predictive of an abnormal SPECT study. The precise 
incidence of silent ischaemia is not clear; Rajagopalan et al. [23] 
recently reported that 58% of asymptomatic patients with type 2 
diabetes had an abnormal SPECT study, whereas Zellweger et 
al. [19] noted that 42% of asymptomatic diabetic patients had an 
abnormal SPECT study. However, these observations demonstrate 
that silent ischaemia is common among patients with type 2 dia-
betes, and screening may be indicated. Whether SPECT imaging 
should be the first line test, however, is still unclear. 
Anand et al. [17] proposed an algorithm for the screening 
of patients with type 2 diabetes for coronary artery disease. The 
authors evaluated asymptomatic patients with type 2 diabetes us-
ing electron beam computed tomography (EBCT). This imaging 
technique allows visualization of atherosclerosis (coronary artery 
calcium) rather than ischaemia, and may thus permit identi-
fication of coronary artery disease at an early stage. Nuclear 
myocardial perfusion imaging was performed in patients with 
calcium score > 100 Agatston units, i.e. 127 (25%) underwent 
gated exercise sestamibi SPECT. For comparison, 53 randomly 
selected patients with a calcium score of 100 also underwent 
SPECT. None of the patients with a calcium score of 10 had 
abnormalities on SPECT. The incidence of abnormal SPECT 
studies increased in parallel with the calcium score, from 18.4% 
in patients with calcium score between 11 and 100 to 71.4% in 
patients with calcium score > 1000. These observations suggest 
that sequential use of EBCT and SPECT may optimize screen-
ing of asymptomatic diabetic patients, and EBCT may be used 
as a gatekeeper for SPECT. This proposal is further strengthened 
by the prognostic data also provided in the study by Anand et al. 
During a mean follow-up of 18 ± 5 months, no events occurred in 
the patients with calcium score ≤ 10, whereas the majority (82%) 
of events occurred in patients with calcium score > 400. Impor-
tantly, on multivariate analysis, the calcium score and the extent of 
SPECT perfusion abnormalities were the only predictors of future 
events. On the basis of this stepwise approach, patients with 
atherosclerosis on EBCT but without ischaemia may be referred 
for risk factor modification, aggressive medical therapy, and 
careful monitoring. Conversely, patients with atherosclerosis and 
ischaemia may be referred for invasive coronary angiography with 
intervention if required. 
The future in non-invasive imaging is very bright. The latest 
application of fusion imaging (SPECT/CT and PET/CT hybrid sys-
tems) allows simultaneous assessment of coronary anatomy and 
physiological significance of the CAD. This will further select the 
patients who need invasive treatment, with previous knowledge of 
coronary anatomy and haemodynamic significance of stenosis, 
and will allow target vessel revascularization.
Stress echocardiography
Stress echocardiographic testing has been shown to provide 
incremental prognostic information in the general population. 
Some studies have demonstrated an incremental value of 
pharmacological and exercise stress echocardiography on the 
prognosis of diabetic persons, specifically [27, 28]. Diabetic pa-
tients had a significantly higher incidence of cardiac events than 
did patients without diabetes [22]. There were more nonfatal 
myocardial infarctions in the diabetic group and a trend toward 
a higher proportion of hard events, including cardiac death. 
The rate of hard events annually was 2.7% in non-diabetic and 
Table 1. Diagnostic accuracy of imaging tests. Reprinted (with permission) from [22]
General population Diabetic patients
Sensitivity Specificity Sensitivity Specificity
Functional imaging [ref.]
Nuclear imaging [11–14] 86 74 80–97 56–88
Stress echocardiography [15–18] 71–84 82–93 81–92 54–88
Contrast echocardiography [21, 22] 89 63 89 52
First-pass perfusion MRI [21] 84 85 NA NA
Stress cine MRI [21] 89 84 NA NA
Anatomical imaging [ref.]
CAC score NA NA NA NA
MRI angiography [27] 72 86 NA NA
MSCT angiography [28, 29] 91 96 95 95
EBCT angiography [30] 87 91 NA NA
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6.0% in diabetic patients. Compared with non-diabetic patients, 
patients with diabetes who have negative stress echocardio-
grams appear to remain at greater risk for cardiac events, pos-
sibly because of a higher prevalence of established coronary 
disease in patients with diabetes. On the basis of limited data, 
it appears that exercise echocardiography offers prognostic 
information in patients with diabetes, but even with negative 
studies, patients with diabetes are at higher risk for cardiac 
events than patients without diabetes. There is limited outcome 
data available that show any benefit of testing in the asympto-
matic population, and thus, routine use of this test cannot be 
widely recommended [29]. Based on our own findings, routine 
screening is recommended for patients in whom the duration of 
type 2 diabetes is > 10 years or even less when more than one 
cardiovascular risk factor is present [30].
Despite the widespread use and reported accuracy of 
stress echocardiography, it is technically challenging, and re-
producibility is still somewhat limited due to high inter-observer 
variability. Standard echocardiographic examinations may be sub-
optimal in quality and frequently do not yield sufficient diagnostic 
information. In diabetic patients, many of whom are overweight, the 
increased weight contributes to a poor echocardiographic image. 
In addition, many diabetic patients cannot exercise adequately 
because of increased weight and neuropathic complications. 
Conflicting results regarding the sensitivity (in the range 60-80%) 
and specificity (44-58%) of stress echocardiography for predict-
ing clinical events in diabetic patients were reported by different 
studies, although these differences did not reach statistical 
significance.22,31 Bax et al. [22] in a review study reported the 
specificity of stress echocardiography in diabetic patients to be 
lower than that of nuclear perfusion imaging. 
However, stress echo offers the advantage of easy portability, 
lower cost, and no radiation exposure compared with nuclear 
stress testing, and it has therefore gained substantial popularity. 
Electron beam tomography measures 
of coronary calcium
Electron-beam CT can be used to measure calcification of 
coronary arteries, an early marker for CAD [20]. This technique 
has substantial potential for risk assessment [21]. However, 
although it can detect the presence of atherosclerosis, it cannot 
measure the severity of obstruction. In addition, a low calcium 
score does not rule out CAD. Because this technique has low 
specificity, the American College of Cardiology does not recom-
mend its routine use in the diagnosis of CAD. Electron-beam 
computed tomography (EBCT) can noninvasively and accurately 
detect coronary calcification, which is a predictor of ischaemic 
heart disease [3]. Plaque calcifications usually precede luminal 
narrowing and the onset of angina symptoms. The sensitivity and 
specificity of EBCT for the detection of stenosis have been reported 
to be > 90% and > 50%, respectively [4]. 
In type 2 diabetic patients, Schurgin et al. [32] showed that 
asymptomatic diabetic patients had a significant increase in the 
prevalence of coronary calcification score compared with matched 
non-diabetic control groups. However, it is not known whether 
coronary calcifications in diabetic patients are associated with 
the presence of significant coronary stenoses. Rumberger et 
al. [33] reported that a coronary calcium score (CCS) of 80 had 
a sensitivity of 84% and a specificity of 84%. These data are in 
keeping with our finding that a CCS of 90 was associated with 
a sensitivity of 75% and a specificity of 75% for the detection of 
significant stenoses in diabetic patients. 
Consequently, coronary calcium is considered an accurate 
marker of atherosclerosis. Though often misrepresented, the 
main purpose of calcium screening is not to identify patients with 
obstructive CAD but to detect vessel wall atherosclerosis. In fact, 
identifying non-obstructive plaque may be as important as as-
sessing stenosis severity since many acute coronary events oc-
cur on the basis of non-obstructive disease in type 2 diabetes. 
Mielke et al. [34] studied a large cohort of patients suffering 
from type 2 diabetes and showed that these patients tend to 
harbour larger amounts of CAC than non-diabetic patients of 
similar age and with a similar risk-factor profile. Moreover, the 
amount of CAC was similar to that of patients with established 
CAD but without diabetes. Similarly, Khaleeli et al. [35] showed 
that asymptomatic diabetic patients present the same preva-
lence of CAC as non-diabetic individuals symptomatic for CAD. 
Furthermore, both studies showed that diabetic women harbour 
as much CAC as diabetic men, confirming the clinical evidence 
that diabetes negates the well-known advantage of women over 
men in prevalence and extent of atherosclerosis. Furthermore, the 
calcium imaging data are supportive of the well-known clinical 
data showing that an asymptomatic diabetic patient presents the 
same cardiovascular risk as a patient with established CAD but 
without diabetes [22].
Recently Raggi et al. [16] published a report of asymptomatic 
individuals, with a large type 2 diabetic subgroup, followed for 
an average of 5 years after having been referred by a primary 
care physician for CAC screening. The risk of all-cause mortality 
was higher in diabetic patients than non-diabetic subjects for 
any degree of calcification, and the risk increased as the calcium 
score increased.
Coronary calcium to assess coronary plaque 
burden and future events
Coronary artery calcium is intimately associated with mural 
atheromatous plaque and is pathognomonic of atherosclerosis. 
Clinical and histopathological studies confirm the close correla-
tion between the extent of coronary artery calcification (CAC) 
and the burden of atherosclerotic coronary disease. The total 
area and volume of coronary artery calcification, determined 
by EBCT, correlates in a linear fashion with the total area of 
coronary artery plaque on a segmental basis [33]. The EBCT 
coronary calcium score may not always predict the existence 
of significant luminal narrowing, but the sensitivity of EBCT to 
detect obstructive luminal disease increases with higher plaque 
burden (especially with an Agatston score of 400 or more) [34]. 
A negative EBCT test (absence of coronary calcium) makes the 
presence of atherosclerotic plaque, including unstable plaque, 
very unlikely — this usually occurs in people with angiographi-
cally normal coronary arteries and is consistent with low risk of 
a cardiovascular event in the next two to five years [37]. The 
extent of CAC predicts the risk of future hard cardiovascular 
events in symptomatic patients and has a better prognostic value 
compared to coronary angiography [38]. Furthermore, there 
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is a direct relationship between increasing calcium scores and the 
occurrence of subsequent cardiac events. Several prospective 
randomised trials have established the predictive value of CAC for 
future coronary events in asymptomatic individuals with varying 
risk factor profiles. A high calcium score (≥ 1,000) on a screen-
ing EBCT in an asymptomatic person predicted a very high risk 
of hard cardiac events (death and MI) in the short term [39]. 
However, none of the 98 patients in the above study underwent 
either non-invasive or invasive testing as a direct consequence 
of their EBCT scores. In the current climate it is unlikely that 
patients with such extensive plaque burden would be untreated, 
and it will be interesting to see whether EBCT could be used to 
monitor therapeutic success. 
It is well known that patients with severe coronary sten-
oses can often be asymptomatic. In diabetic patients without 
cardiac symptoms or signs but with other cardiovascular risk 
factors, silent myocardial ischaemia has been found in 10–30% 
of cases [31]. 
In a recent study of type 2 diabetic patients, Rutter et al. [31] 
found that silent myocardial ischaemia was the strongest inde-
pendent predictor of future CHD events. In a comparative study 
Schurgin et al. [32] showed that patients with type 2 diabetes have 
a significantly higher prevalence of CAC scores > 400, consist-
ent with a greater atherosclerotic plaque burden compared with 
randomly selected and matched non-diabetic control groups. 
This leads us to an important question: Who should be screened 
by EBCT? 
After evaluating the existing literature on EBCT coronary 
calcium imaging in 2000, The American College of Cardio-
logy/American Heart Association joint task force on clinical 
expert consensus documents concluded that EBCT has a role in 
selected asymptomatic patients in whom standard risk assess-
ment is considered insufficient [15, 37]. Since age appears to 
be a surrogate marker for the total coronary atherosclerotic 
plaque burden, it has also been suggested that the coronary 
calcium score should replace age as a risk factor in Framing-
ham scoring for CAD risk assessment. EBCT coronary calcium 
imaging plays an important role in the accurate risk stratification 
of asymptomatic patients with one or more conventional risk 
factors for coronary disease, in whom clinical decision making 
regarding the need for medical intervention can often be uncer-
tain. Currently the best example of this strategy is with regard 
to the decision of whether to institute cholesterol-lowering and 
antiplatelet drug therapy. 
Magnetic resonance imaging
High-resolution magnetic resonance (MR) is a non-invasive 
imaging technique with excellent soft-tissue contrast that dif-
ferentiates plaque components on the basis of biophysical and 
biochemical parameters. Further improvement in external coils and 
the use of contrast agents that enhance the different vessel wall 
components hold great promise and may make MR suitable for 
clinical use in atherosclerotic plaque diagnosis and in monitoring 
Figure 1. Algorithm for diagnosis and treatment of CAD in diabetic patients. Reprinted (with permission) from [16].
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therapeutic efficacy [40]. Future work in coronary MR plaque ima-
ging will certainly aim at the identification of the different plaque 
components, with increasing focus on persons with diabetes. 
This may enable identification of vulnerable plaques before they 
rupture and may provide a way to target pharmacological interven-
tion to reduce or prevent coronary disease. The assessment of 
atherosclerotic plaques by imaging techniques may prove valuable 
for the identification of vulnerable plaques. In vivo high-resolution 
multicontrast MR holds promise for noninvasively imaging vul-
nerable plaques and characterizing the different components in 
all arteries, including the coronary arteries. MR stress testing 
provides important incremental information about clinical risk fac-
tors and resting wall motion abnormalities in a high risk patients, 
including those with diabetes [41].
Magnetic resonance angiography in peripheral 
arterial disease
Magnetic resonance angiography (MRA) is useful in the 
diagnosis of anatomic lesions and the grade of peripheral artery 
stenosis after a functional study with indexes is conducted. Se-
lection of the suitability of a lesion for percutaneous revasculari-
zation is a second indication for its usage. Both indications are 
applied in peripheral arterial disease subjects including diabetic 
subgroups with IA levels of evidence according to AHA/ACC 
Guidelines [42]. Magnetic resonance angiography for extremi-
ties should be performed with gadolinium enhancement. Andreisek 
et al. [43] presented time-resolved imaging of contrast kinetics MR 
angiography of the distal calf and pedal vessels as superior to 
standard MR angiography regarding the number of diagnostic 
segments and assessment of the degree of luminal narrowing in 
diabetics. Therefore, MRA should be part of the diagnostic algo-
rithm for patients in whom pedal bypass grafting is a therapeutic 
option [44]. MR angiography of intracranial arteries has been 
recognized as useful in patients with intracranial steno-occlusive 
lesions and either diabetes or the presence of risk factors. These 
patients could be followed up by serial MR angiography of intrac-
ranial arteries [45]. 
Multi-sliced MSCT angiography
In the last 10 years computed tomography (CT) has pro-
gressed from single-slice scanners to the current generation of 
64-slice machines that can image the whole heart in seconds with 
sub-millimetre resolution. Consequently, multislice computed 
tomography (MSCT) scanning is rapidly gaining acceptance 
as an alternative to conventional X-ray coronary angiography. 
64–slice MSCT angiography can quickly and accurately detect 
coronary stenosis in a way that is convenient to patients. Diabetic 
patients with borderline myocardial perfusion imaging findings of 
moderate ischaemia should be referred for MSCT angiography. 
Patients with severe, extensive ischaemia are directed to invasive 
coronary angiography. There are currently no published guide-
lines for the clinical application of CT coronary angiography. 
Patients who have chest pain, but who are of low-to-moderate 
risk or have equivocal stress tests are ideal candidates for CT 
coronary angiography, as are patients who are asymptomatic 
but who are a very high risk for early or severe cardiovascular 
disease. For particularly anxious patients with atypical chest pain, 
the combination of a low-risk stress test and a negative CT coro-
nary angiogram is a powerful tool for reassurance. Often more 
importantly, the ability to demonstrate mild coronary atherosclero-
sis can lead to lifestyle and diet changes, as well as encouraging 
compliance with medical therapy. There are situations in which CT 
coronary angiography is useful after an invasive catheterisation 
has already been performed. MSCT is particularly well suited 
for defining the exact origin and course of anomalous coronary 
arteries identified by conventional coronary angiography. Like 
intravascular ultrasound, MSCT is able to demonstrate pathol-
ogy in the wall of the artery, and not just define obstruction of 
the lumen. In this manner, a coronary angiogram can often give 
a more total view of coronary pathology, including evaluation of 
the lumen, the amount of soft, fatty plaque, and calcified plaque 
burden in the coronary vasculature. Romeo et al. [46] in their 
study calculated the value of multislice computed tomography 
for early detection of significant coronary artery disease (CAD) in 
high-risk asymptomatic subjects. Selective coronary angiography 
confirmed the results of multislice computed tomography in 99% 
of asymptomatic subjects with more than one major risk factor 
(hypertension, diabetes, hypercholesterolaemia, family history, 
or smoking) and an inconclusive or unfeasible noninvasive 
stress test result (stress electrocardiography, echocardiography, 
or nuclear scintigraphy) [47]. Multislice computed tomography 
displayed single-vessel CAD in 16% of patients, 2-vessel CAD 
in 7%, and 3-vessel CAD in 4%. Sensitivity and specificity of 
MSCT coronary angiography were 100% and 98%, respectively, 
with a positive predictive value of 95% and a negative predictive 
value of 100%. MSCT is also very well suited to evaluating the 
patency of coronary bypass grafts, and in some cases may obvi-
ate the need for stress testing in patients who have undergone 
bypass surgery.
Multi-sliced CT angiography in peripheral arterial 
disease (PAD)
Multi-sliced ct angiography (MSCT) angiography has not been 
established as a routine screening method for detection of PAD 
in diabetics. It could be used for the detection of anatomical le-
sions in leg ischaemia patients when revascularization is indicated 
and in those with conflicted reports of vascular duplex ultrasound. 
It is considered as a substitute for MRA for patients with contrain-
dications for MRA [48].
Vascular ultrasound
Carotid ultrasound examination is indicated in the presence 
of stroke [49]. Ultrasound capabilities facilitate decision making 
regarding the appropriateness of medical therapy or surgical in-
tervention in these individuals. Significant grade (> 60%) carotid 
stenosis in diabetic patients needs elective endarterectomy or 
carotid stenting as the preferable method when high risk exists. 
Patients with stroke caused by non-significant carotid artery dis-
ease should be aggressively medically treated [6]. 
General screening for carotid artery disease is not recom-
mended in most guidelines regarding diabetes. This is due 
to the low prevalence (4.5%) of significant carotid stenosis in 
asymptomatic subjects and to the costs of equipment and 
training [50].
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Focused carotid screening in diabetics is recommended 
where cervical bruits exist and in subjects with symptomatic or 
asymptomatic PAD, defined by ankle-brachial index. Since the 
prevalence of diabetes increases constantly, Duval et al. [51] 
suggested updating the criteria for the selection of diabetics for 
carotid ultrasound; it could be also recommended for diabetic 
patients with coronary disease, all diabetic patients above 60 
years of age, smokers, hypertensive with hypercholesterolaemia, 
and all type 2 diabetic patients with renal failure and long duration 
ill-controlled diabetes. 
Nowadays there is no doubt that carotid intima media thick-
ness can predict total cardiovascular events [52]. Carotid intima 
media thickness reflects the cumulative effect of risk factor expo-
sure, and it is obvious that it can predict future risk. Carotid intima 
media thickness measurement may contribute to elucidating 
the effect of intervention on the rate of change in relation to the 
levels of various risk factors [53]. Carotid intima media thick-
ness has been shown to have progressed significantly more in 
diabetic patients who received standard therapy than in those 
with intensive therapy.
 Some recent studies show carotid plaque as a superior 
predictor of underlying CAD and future events than intima media 
thickness [54, 55]. All these studies include large subgroups of 
diabetics. Particularly for the diabetic population, Lee and Mat-
sumoto independently presented an association of increased 
carotid intima media thickness and plaque with acute ischaemic 
stroke in type 2 diabetic patients [56]. The prevalence of carotid 
artery disease in a mean of plaque presence in diabetics is over 
50%. Advanced carotid atherosclerosis is closely related with 
glycaemia, the lipid profiles of these patients, and responses to 
the patient’s own risk factor burden [57–58]. 
Ultrasound measurement of progression of carotid athero-
sclerosis, plaque area, and volume (with using 3D-acquision 
for the last one) have been found to be closely linked with 
type 2 diabetes and vascular events in the general population 
[59]. Perhaps the application of this method has future pos-
sibilities and additional clinical usefulness in risk stratification 
of these patients.  
Duplex ultrasound of the leg arteries is useful to diagnose the 
anatomic location and degree of stenosis of peripheral arterial 
disease and to provide surveillance following femoral-popliteal 
bypass and endovascular intervention. In all of these cases, 
continuous Doppler with index measurement is the first method 
of choice [48]. Few studies have described femoral artery intima 
media thickness as a prognostic parameter of type 2 diabetic 
patients, but its use as not as robust as carotid intima media 
thickness has to be. 
Conclusions
The number of patients with type 2 diabetes will increase 
dramatically over the next few years. The preclinical diagnosis of 
coronary artery disease is effective in reducing the risk of cardiac 
events in subjects with diabetes mellitus who are at high cardio-
vascular risk. Management guidelines suggest non-invasive ima-
ging techniques, such as nuclear myocardial perfusion imaging 
and stress echocardiography, for the detection of coronary artery 
disease in patients with symptoms of coronary artery disease. 
Although a substantial amount of patients may have silent ischae-
mia, not all patients may benefit from imaging to detect ischaemia. 
A stepwise screening with assessment of atherosclerosis by EBCT, 
followed by SPECT if needed, may allow optimal risk stratification 
of asymptomatic diabetes. Carotid intima media thickness has also 
been defined as a useful tool in risk stratification algorithm of 
diabetics. Screening for peripheral arterial disease and carotid 
artery disease should be mandatory for diabetic subjects, not only 
as a way of looking for the polyvascular disease, but also as a way 
of looking into the diabetic heart. 
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